Literature DB >> 3118442

Vascular damage and factor-VIII-related antigen in the rheumatic diseases.

J J Belch1, A A Zoma, I M Richards, K McLaughlin, C D Forbes, R D Sturrock.   

Abstract

Factor-VIII-Related antigen (VIII R:Ag) is known to be produced by the blood vessel wall. Noxious stimuli increase endothelial release of VIII R:Ag. It might be expected that the development of vasculitis would be associated with increased levels of VIII R:Ag. To investigate this, eight different groups of subjects were studied: 25 patients with systemic sclerosis, 19 with systemic lupus erythematosus, 15 with rheumatoid arthritis (RA) plus vasculitis, 19 with systemic vasculitis and 14 with atherosclerosis. These groups were compared to 29 patients with primary Raynaud's disease, 15 with RA without vasculitis and 50 controls. Results showed that where there was evidence of vascular disease, then VIII R:Ag was elevated. VIII R:Ag appeared to be a more specific marker for vascular damage than erythrocyte sedimentation rate or C-reactive protein. Longitudinal studies in 11 patients showed good correlation between progression of vascular disease and VIII R:Ag.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3118442     DOI: 10.1007/bf00270462

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  11 in total

1.  Electroimmuno assay.

Authors:  C B Laurell
Journal:  Scand J Clin Lab Invest Suppl       Date:  1972

2.  Aggregation of human platelets by purified porcine and bovine antihaemophilic factor.

Authors:  C D Forbes; C R Prentice
Journal:  Nat New Biol       Date:  1973-01-31

3.  Decreased plasma fibrinolysis in patients with rheumatoid arthritis.

Authors:  J J Belch; B McArdle; R Madhok; K McLaughlin; H A Capell; C D Forbes; R D Sturrock
Journal:  Ann Rheum Dis       Date:  1984-12       Impact factor: 19.103

4.  Studies on the prolonged bleeding time in von Willebrand's disease.

Authors:  P M Mannucci; F I Pareti; L Holmberg; I M Nilsson; Z M Ruggeri
Journal:  J Lab Clin Med       Date:  1976-10

5.  Evaluation and management of patients with Raynaud's syndrome.

Authors:  J M Porter; S P Rivers; C J Anderson; G M Baur
Journal:  Am J Surg       Date:  1981-08       Impact factor: 2.565

6.  Factor VIII concentrate prepared from DDAVP stimulated blood donor plasma.

Authors:  I M Nilsson; H Walter; M Mikaelsson; H Vilhardt
Journal:  Scand J Haematol       Date:  1979-01

7.  Synthesis of von Willebrand factor by cultured human endothelial cells.

Authors:  E A Jaffe; L W Hoyer; R L Nachman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-05       Impact factor: 11.205

8.  Coagulation and fibrinolysis study in systemic lupus erythematosus: haematological, urinary and tissue parameters.

Authors:  P Stratta; C Canavese; P Valmaggia; M Rotunno; E Levi; A Bulla; A Vercellone
Journal:  Thromb Haemost       Date:  1981-10       Impact factor: 5.249

9.  1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases.

Authors:  P M Mannucci; Z M Ruggeri; F I Pareti; A Capitanio
Journal:  Lancet       Date:  1977-04-23       Impact factor: 79.321

10.  Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease.

Authors:  C A Ludlam; I R Peake; N Allen; B L Davies; R A Furlong; A L Bloom
Journal:  Br J Haematol       Date:  1980-07       Impact factor: 6.998

View more
  22 in total

1.  Raised concentrations of von Willebrand factor antigen in systemic sclerosis.

Authors:  A D Blann; K J Illingworth; M I Jayson
Journal:  Ann Rheum Dis       Date:  1991-05       Impact factor: 19.103

2.  Damage to the endothelium in Sjögren's syndrome: lack of correlation with antinuclear antibody titre and presence of antibodies to SSA or SSB autoantigens.

Authors:  A D Blann; A C Wainwright; P Emery
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

3.  Plasminogen activator inhibitor and von Willebrand factor in polymyalgia rheumatica.

Authors:  A Uddhammar; S Rantapåå-Dahlqvist; T K Nilsson
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

4.  Vascular damage in Wegener's granulomatosis and microscopic polyarteritis: presence of anti-endothelial cell antibodies and their relation to anti-neutrophil cytoplasm antibodies.

Authors:  C O Savage; B E Pottinger; G Gaskin; C M Lockwood; C D Pusey; J D Pearson
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

Review 5.  Raynaud's phenomenon: its relevance to scleroderma.

Authors:  J J Belch
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

6.  Endothelial cell damage in rheumatoid disease correlates with complement consumption and immune complexes.

Authors:  A D Blann
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

7.  Anti-endothelial cell antibody, thrombomodulin, and von Willebrand factor in idiopathic inflammatory myopathies.

Authors:  K V Salojin; A Bordron; E L Nassonov; V Z Shtutman; N G Guseva; A A Baranov; I N Targoff; P Youinou
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

8.  Von Willebrand factor antigen in assessment of vasculitis in patients with connective tissue diseases.

Authors:  J Kloczko; A Kuryliszyn-Moskal; K Bernacka; M Bielawiec; B Cylwik; P Radziwon
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

9.  Soluble cell adhesion molecules and von Willebrand factor in children with Kawasaki disease.

Authors:  M C Nash; V Shah; M J Dillon
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

10.  Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon.

Authors:  C S Lau; M McLaren; I Mackay; J J Belch
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.